Related Experiment Videos
Hyperglobulinemia in amiodarone-induced pneumonitis
Meir Mouallem1, Natalia Antipov, Haim Mayan
1Department of Medicine E, Sheba medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, 52621, Israel. mouallem@post.tau.ac.il
Cardiovascular Drugs and Therapy
|March 16, 2007
Summary
Amiodarone treatment may cause hyperglobulinemia in some patients, often linked to amiodarone-induced pneumonitis. This condition may indicate organ damage or play a role in developing pneumonitis.
Area of Science:
- Cardiology
- Pulmonology
- Clinical Pharmacology
Background:
- Amiodarone is an effective antiarrhythmic drug with known side effects.
- Hyperglobulinemia has not been previously associated with amiodarone treatment.
Purpose of the Study:
- To investigate the association between amiodarone therapy and hyperglobulinemia.
- To determine if amiodarone causes a general increase in serum globulin levels.
Main Methods:
- Identified 15 patients who developed hyperglobulinemia during amiodarone therapy.
- Measured serum globulin levels before, during, and after amiodarone treatment.
Main Results:
- Serum globulin levels significantly increased during amiodarone therapy (2.48 to 4.11 g/dL, p=0.001) and decreased after discontinuation (to 2.80 g/dL, p=0.001).
- 11 of 15 patients required amiodarone cessation due to complications, primarily pneumonitis (9 patients).
- No significant difference in serum globulin was observed between amiodarone-treated patients and those with ischemic heart disease not on amiodarone.
Conclusions:
- Amiodarone therapy can be associated with hyperglobulinemia in some individuals.
- Hyperglobulinemia in this context is often linked to amiodarone-induced toxicity, particularly pneumonitis.
- Hyperglobulinemia may serve as a marker for organ damage or contribute to pneumonitis pathogenesis.
Related Concept Videos
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...